Document Detail

Management of unstable arrhythmias in cardiogenic shock.
MedLine Citation:
PMID:  21626366     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Atrial and ventricular arrhythmias commonly arise in the setting of cardiogenic shock and often result in hemodynamic deterioration. Causative factors include myocardial ischemia, volume overload, and metabolic disturbances. Correcting these factors plays an important role in managing arrhythmias in this setting. Ventricular arrhythmias are more ominous compared to atrial arrhythmias but both require prompt intervention with electrical shock and anti-arrhythmic drug suppression. Coronary reperfusion is key to improving survival, including reducing the risk of sudden cardiac arrest, in acute myocardial infarction. Case series have also demonstrated the value of intra-aortic balloon pump counter-pulsation in suppressing ventricular arrhythmias in cardiogenic shock. The mechanism of arrhythmia suppression may be due to improved coronary perfusion and afterload reduction. Percutaneous ventricular assist device placement may be effective in this setting; however, data addressing this specific endpoint are lacking. Anti-arrhythmic drug options for ventricular and atrial arrhythmia suppression, in the setting of cardiogenic shock, are relatively limited. Common class I agents are excluded due to the inherent abnormal cardiac structure and function in the setting of cardiogenic shock. Class III drug options include dofetilide and amiodarone. The other Class III agents, sotalol and dronedarone, are excluded due to associated mortality observed in the SWORD and ANDROMEDA trials, respectively. Dofetilide is renally excreted and causes QT interval prolongation. Care should be taken to avoid excessive drug accumulation due to poor kidney perfusion and function. Dofetilide is approved for use for atrial arrhythmias and has not been studied for ventricular arrhythmia suppression. The DIAMOND-CHF trial established its safety in the setting of heart failure. Amiodarone is very effective in suppressing both atrial and ventricular arrhythmias. It is often the drug of choice in heart failure. Its off-label use for atrial arrhythmias is very common. Care should be taken with intravenous amiodarone to avoid hypotension.
Abdulfattah Saidi; Nazem Akoum; Feras Bader
Related Documents :
22347646 - Short-term effects of ketamine and isoflurane on left ventricular ejection fraction in ...
21713516 - 3d dynamic position assessment of the coronary sinus lead in cardiac resynchronization ...
22519686 - Acute and long-term cardiomyopathy and delayed neurotoxicity after accidental lasalocid...
7690096 - Systemic and coronary effects of the angiotensin ii receptor antagonist exp3174 in dogs.
1495286 - Hemodynamic evaluation of heterotopic heart transplantation.
17060106 - Characterization of microvascular dysfunction after acute myocardial infarction by card...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  13     ISSN:  1534-3189     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-11     Completed Date:  2011-07-14     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  354-60     Citation Subset:  -    
Division of Cardiology, University of Utah School of Medicine, 30 North 1900 East, Room 4A100, Salt Lake City, UT, 84132, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The limiting behaviour of a mainland-island metapopulation.
Next Document:  Distribution of Microfossils Within Polymetallic Nodules: Biogenic Clusters Within Manganese Layers.